Estimating The Appropriate Size Of Global Pull Incentives For Antibacterial Medicines-Reference-Cited by-同舟云学术

Estimating The Appropriate Size Of Global Pull Incentives For Antibacterial Medicines

Published:2021-11-01 Issue:11 Volume:40 Page:1758-1765
ISSN:0278-2715
Container-title:Health Affairs
language:en
Short-container-title:Health Affairs

Author:

Outterson Kevin¹

Affiliation:

1. Kevin Outterson () is a professor in the School of Law and executive director of CARB-X, a grant-funded project at the School of Law, Boston University, in Boston, Massachusetts.

Publisher

Health Affairs (Project Hope)

Subject

Health Policy

Reference19 articles.

1. Patient Access in 14 High-Income Countries to New Antibacterials Approved by the US Food and Drug Administration, European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, or Health Canada, 2010–2020

2. Antibacterial R&D at a Crossroads: We’ve Pushed as Hard as We Can … Now We Need to Start Pulling!

3. A shot in the arm for new antibiotics

4. Financing Pull Mechanisms for Antibiotic-Related Innovation: Opportunities for Europe

5. Reimbursement models to tackle market failures for antimicrobials: Approaches taken in France, Germany, Sweden, the United Kingdom, and the United States

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancing global antibiotic research, development and access;Nature Medicine;2024-09-03

2. Changes in revenues associated with antimicrobial reimbursement reforms in Germany;Humanities and Social Sciences Communications;2024-08-10

3. A Review of Antibacterial Candidates with New Modes of Action;ACS Infectious Diseases;2024-07-17

4. Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance;The Lancet;2024-06

5. Implementing an EU pull incentive for antimicrobial innovation and access: blueprint for action;The Lancet Microbe;2024-06